The cost of Mounjaro (tirzepatide) is a significant consideration for UK patients purchasing it privately. With monthly costs often exceeding £150-£200, the prospect of a cheaper generic version is naturally appealing. Here is what we currently know about the timeline and prospects for generic tirzepatide.
Understanding Patent Protection
Eli Lilly holds multiple patents on tirzepatide, covering the molecule itself, the manufacturing process, the formulation, and the delivery device. In the UK and Europe, patent protection for the active substance is expected to extend into the mid-to-late 2030s, with supplementary protection certificates potentially extending coverage further.
This means that a legally marketed generic version of tirzepatide is unlikely to appear in the UK for at least a decade.
Biosimilars vs Generics
An important distinction to understand is that tirzepatide, as a peptide medication, would not have a traditional "generic" in the way that simple chemical drugs do. Instead, it would require a biosimilar:
- Generics are chemically identical copies of small-molecule drugs and require relatively simple regulatory approval
- Biosimilars are highly similar but not identical copies of biological medicines and require extensive clinical testing to demonstrate comparable safety and efficacy
- Biosimilar development typically costs £100-200 million and takes 7-8 years
What About International Competition?
Several developments may influence future pricing, even before patents expire:
- New competitor medications entering the market may drive prices down through competition
- Increased manufacturing capacity for tirzepatide may reduce costs over time
- NHS negotiation — the NHS has significant purchasing power and negotiates confidential discounts on list prices
- International reference pricing may influence UK prices if tirzepatide becomes cheaper in comparable markets
Compounding and Counterfeit Risks
UK patients should be aware of risks associated with seeking cheaper alternatives:
- Compounded tirzepatide from unregulated sources may not meet safety or quality standards
- Counterfeit medications sold online pose serious health risks and are a growing problem
- The MHRA regularly issues warnings about fraudulent weight loss medications
- Always purchase from GPhC-registered pharmacies — tools like MedsLens only list registered, legitimate UK pharmacies
Reducing Your Current Costs
While waiting for prices to decrease naturally, UK patients can take practical steps:
- Compare prices across multiple registered pharmacies using MedsLens — prices can vary by £20-50 per pen
- Check NHS eligibility — you may qualify for NHS-funded treatment, which costs only the standard prescription charge
- Look for pharmacy loyalty programmes or subscription models that may offer modest savings
- Ask about patient access schemes — Eli Lilly occasionally runs programmes to support treatment access
The Bottom Line
A generic or biosimilar version of tirzepatide is not expected in the UK before the late 2030s at the earliest. However, increasing competition from other weight management medications and NHS negotiation may help moderate prices in the nearer term.